Shares of life sciences company Revvity (NYSE:RVTY) fell 7.6% in the afternoon session after the company lowered its ...

Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.

The Food & Drug Administration is investigating the death of an 8‑year‑old following Elevidys gene therapy for Duchenne ...

US stocks end up on earnings, data showing a resilient economy and trade deall optimism. S&P 500 and Nasdaq score records again.

Separately, Sareptea said last week that it would pause the development of most of its experimental gene therapies for a different type of muscular dystrophy. The stoppage came after one of the ...

View the latest Sarepta Therapeutics Inc. (SRPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.

According to Endpoints News, FDA officials stated that the Center for Biologics Evaluation and Research (CBER) review staff are "unanimous" that Elevidys should never return to market. The report ...

There are about $10.5 billion of biotech convertibles outstanding, roughly 3% of the $305 billion market, according to BofA Securities.

Opendoor Technologies shares are up nearly 12% as traders continue to buy the meme stock after [Monday's extreme volatility]( ...

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Wall Street traders gearing up for the start of the megacap earnings season sent stocks wavering near a record, with ...

A slide in several big techs dragged down stocks ahead of the start of a high-stakes earnings season, while Microsoft Corp.